Actelion's Annual General Meeting of Shareholders held in Basel

Actelion's Annual General Meeting of Shareholders held in Basel. End Quote

(1888PressRelease) May 07, 2011 - The meeting was attended by 486 shareholders, representing 78'430'215 shares or 60.41 % of the total outstanding shares.

Shareholders approved the Business Report, consisting of the Annual Report, the Annual Statutory Accounts and the Consolidated Accounts for the year 2010.

A proposal by the Board to appropriate available earnings from capital contribution and distribute as a dividend in the amount of CHF 0.80 per registered share, was passed by shareholders.

A request for information from a shareholder was addressed by the Board of Directors and a further request for a special audit "Sonderprüfung" was rejected.

Shareholders granted discharge to all members of the Board of Directors and of the Senior Management.

A proposal by the Board to approve the continuation of a share repurchase program, of up to CHF 800 million, which commenced in November 2010, was passed by shareholders.

Shareholders voted on a number of resolutions to amend Actelion's Articles of Association as follows:

A proposal to introduce a consultative vote on the Compensation Report was approved.
A proposal regarding the implementation of the Book Entry Securities Act was approved.
A proposal to remove the maximum limit in number of Board Members was rejected.
A proposal to reduce the Term of Office for Board Members to one year was rejected.
A proposal that Shareholders should elect the Chairman of the Board at the AGM was rejected.

Shareholders voted against a proposal from the Requesting Shareholder to remove five members of the current Board.

Actelion's shareholders voted to re-elect Dr. Jean-Paul Clozel, Mr. Juhani Anttila, and Mr. Carl Feldbaum to the Board for a term of three years.

Shareholders also voted to elect two new Directors, Dr. Jean-Pierre Garnier and Mr. Robert Bertolini to the Board for a term of three years.

Following the AGM, Actelion's Board comprises a total of eleven members: Robert E. Cawthorn (Chairman), Jean-Pierre Garnier (Vice-Chairman), Joseph C. Scodari (Vice-Chairman), Juhani Anttila, Robert Bertolini, Jean-Paul Clozel, Carl Feldbaum, Werner Henrich, Michael Jacobi, Armin Kessler, and Jean Malo.

Finally, shareholders confirmed Ernst & Young as the Company's statutory auditors for the year 2011.

Actelion Ltd.

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,400 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI).

For further information please contact:

Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36

###

space

Other Related Press Releases